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Summary
Vanadate is known for mimicking insulin action through activation of
insulin and/or insulin like growth factor 1 (IGF 1) receptors. Vanadate insu-
lin-like effect on bone-related metabolism has been previously investigated
using mammalian in vitro cell systems but other vertebrate systems have
rarely been used. We have recently demonstrated the suitability of a fish bone
derived cell line (VSa13) to study anti-mineralogenic effects of vanadate.
Here, we propose that vanadate stimulation of cell proliferation involves MAPK
signalling pathway and IGF 1 receptor activation, while impairment of extra-
cellular matrix (ECM) mineralization is likely to involve both MAPK and PI
3K pathways and insulin receptor activation.
Introduction
Vanadium is recognized as an important trace element in living organisms
(1,2). In mammals, one of its key features is its ability to mimic insulin and
IGF-1 (3,4), demonstrated in vivo using streptozocin-treated rats (5,6) and in
vitro using adipocyte cultures (7,8). Insulin-like action of vanadium (in par-
ticular vanadate) has been associated with inhibition of protein tyrosine
phosphatases (PTPases) and consequent activation of tyrosine kinase receptors (9)
such as those for insulin and IGF 1. Deprivation of vanadium in goat diet
induces severe bone malformation (10), suggesting its requirement for spe-
cific growth factor-dependent signalling. In the last decade, effects on bone
metabolism were investigated using mouse bone derived cell lines (11) and
more recently the fish bone derived cell line VSa13 (12,13) where vanadium
compounds and salts have been shown to: a) down regulate alkaline
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phosphatase and PTPases activity, b) stimulate type I collagen synthesis and
cell proliferation, c) impair ECM mineralization, and d) activate insulin and
IGF-1 signalling pathways. Data related to vanadium effects on bone metabo-
lism are however still controversial. In this paper, proliferative and anti-mineralogic
effects of vanadate were investigated in vitro using VSa13 cells, then com-
pared to those of insulin and IGF-1, and finally characterized in the presence
of known inhibitors of mitogen activated protein kinase (MAPK) and
phosphatidylinositol-3 kinase (PI 3K) pathways.
Materials and methods
VSa13 cells were maintained in DMEM as previously described (13,14);
Vanadate solutions were prepared and characterized as described by Tiago and
colleagues (13). Bovine insulin peptide (Sigma Aldrich) solution was pre-
pared at 10 µM in pH 2.0 milliQ water. Pagrus auratus IGF 1 mature peptide
(Novozymes Gropep) solution was prepared at 0.1 µg/µl in milliQ water.
PD98059 and wortmannin solutions were prepared in dimethyl sulfoxide at 6
and 10 mg/ml, respectively; Proliferation of VSa13 cells was determined using
CellTiter 96 non radioactive proliferation assay kit (13); Mineral deposition
was determined by von Kossa staining and quantified using densitometric
method (13).
Results and discussion
Dividing VSa13 cells were untreated or treated with 0.1 µM wortmannin
(PI-3K pathway inhibitor), 100 µM PD98059 (MAPK pathway inhibitor), and/
Figure 1: Effect of vanadate, insulin, IGF 1, wortmannin and PD98059 on VSa13 cell
proliferation (data from at least 3 independent experiments; asterisk = statistically different
from controls, P<0.05, one-way ANOVA).
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or 7.5 µM metavanadate. In separated experiments, cells were also treated
with 10 nM insulin or IGF 1. Vanadate stimulated VSa13 cell proliferation in
a PD98059-dependent manner, suggesting the involvement of MAPK path-
way (Figure 1). Comparable effects were observed in mammals using TreVO-
treated cells (15), suggesting similar mechanisms in fish and mammals. Vana-
date proliferative effect was comparable to that induced by IGF 1, but not by
insulin, in agreement with the higher capacity of IGF 1 receptor (compared
to IR) to activate MAPK pathway in mammals (16).
Mineralizing VSa13 cells were treated as above but for a longer time (4
weeks). Insulin and vanadate, but not IGF 1, inhibited ECM mineralization by
30 and 90%, respectively (Figure 2). These anti-mineralogic effects were totally
or partially (60-70%) reverted, respectively, in the presence of PD98059 or
wortmannin. Involvement of both MAPK and PI 3K pathways in mediating
vanadate and insulin effects in fish cells is consistent with recent observation
of strong anti mineralogenic effects in MC3T3 E1 cells through PI 3K\ras\ERK
pathway activation (17). IGF 1 mitogenic effects are consistent with previous
observations in mammalian systems (18), but to date there is no clear asso-
ciation with increased in vitro mineral deposition, although increased bone
turnover in vivo has been suggested (19)
Figure 2: Effect of vanadate, insulin, IGF 1, wortmannin and PD98059 on VSa13 ECM
mineralization (data from at least 3 independent experiments; asterisk = statistically differ-
ent from controls, P<0.05, one-way ANOVA).
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